Compare HCA Health Inc (HCA) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Johnson & Johnson — how do they compare? HCA Health Inc trades at $408.7 (market cap $89.08B), while Johnson & Johnson trades at $260.26 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 7× HCA Health Inc's market cap, and Johnson & Johnson pays the higher dividend (2.06%). Which is the better fit depends on your goals.
| HCA | JNJ | |
|---|---|---|
Market Cap | $89.08B | $626.09B |
Sector | Health | Health |
52-Week High | $545.13 | $267.24 |
52-Week Low | $361.32 | $172.78 |
Enterprise Value | $139.62B | $654.37B |
Dividend Yield | 0.76% | 2.06% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $414.03, up 0.16% today, with strong technical momentum as price sits above key support levels. The company demonstrates solid fundamentals with Q2 2026 earnings beating estimates, revenue growth to $75.6B in 2025, and consistent dividend payments. Recent management appointments signal strategic focus on clinical operations and ambulatory services.
HCA presents a compelling investment case with attractive valuation (P/E 13.8), analyst consensus price target of $449.93 (8.7% upside), and strong institutional support. However, risks include ongoing legal investigations, rising expenses impacting margins, and high debt levels at 80.9% debt-to-asset ratio that could constrain financial flexibility.
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
